Home›Oncology› Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancer
Bibliometric analysis maps research trends and key contributors in immune checkpoint inhibitors for endometrial cancerMapping the Research Landscape of Immune Therapy for Endometrial Cancer
Frontiers in MedicinePublished June 8, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that this bibliometric analysis maps research trends rather than providing clinical trial efficacy data.
This systematic review utilizes a bibliometric analysis to evaluate the research landscape regarding immune checkpoint inhibitors in the treatment of endometrial cancer. The scope includes an analysis of knowledge frameworks, key contributors, and emerging research hotspots across two major databases: WoSCC (829 publications) and PubMed (279 publications).
Key findings identify significant research focus on microsatellite instability, mismatch repair deficiency, PD-1, PD-L1, chemotherapy, pembrolizumab, lenvatinib, and dostarlimab. The analysis identifies the United States, China, and Italy as leading contributing countries, with the highest level of international collaboration occurring between the United States and England. Influential journals identified include Gynecologic Oncology, Cancers, Frontiers in Immunology, Frontiers in Oncology, and the Journal of Clinical Oncology.
This study serves to map academic trends and identify influential institutions and authors rather than providing clinical efficacy data for specific medications. It highlights that research is heavily concentrated on mismatch repair deficiency and specific agents like pembrolizumab and lenvatinib. The findings are useful for identifying key contributors and emerging topics in the field, but do not provide direct evidence for clinical practice changes.
This study is a bibliometric analysis, which means it maps out existing research trends rather than testing new treatments on patients. It looked at hundreds of published papers to identify who is leading the research and what specific topics are gaining the most attention in the field of endometrial cancer.
The researchers identified key areas of interest, such as microsatellite instability and specific drugs like pembrolizumab and lenvatinib. The analysis also highlighted that international collaboration is high, particularly between the United States and England. It shows which journals and countries are contributing the most to this area of medicine.
Because this study maps existing literature rather than testing drug effectiveness, it does not provide information on how well these treatments work for patients or what side effects they may cause. It serves as a guide for researchers to see where the field is moving. Patients should view this as a map of scientific activity rather than a guide for clinical treatment choices.
What this means for you:
This study maps research trends and identifies key contributors in immune therapy for endometrial cancer.
BackgroundEndometrial cancer represents one of the most prevalent gynecological malignancies. This study aims to systematically analyze the knowledge frameworks, key contributors, research hotspots, emerging trending topics, and future directions in the field of immune checkpoint inhibitors for endometrial cancer by applying bibliometric methodologies.MethodsA thorough and methodical search of the Web of Science Core Collection (WoSCC) database and the PubMed database was performed to identify publications related to immune checkpoint inhibitors in endometrial cancer from January 1, 2015, to December 31, 2024. Furthermore, bibliometric analysis and knowledge map visualization were conducted utilizing VOSviewer, Biblioshiny, and CiteSpace.ResultsFor the WoSCC database, this research involved an analysis of 829 publications disseminated across 296 journals, authored by 5,145 researchers affiliated with 1,535 institutions from 63 different countries. For the PubMed database, this research involved an analysis of 279 publications disseminated across 120 journals, authored by 1,611 researchers affiliated with 974 institutions from 46 different countries. The leading three contributors to publication volume were United States, China, and Italy. Importantly, the highest level of international collaboration has been recorded between United States and England. Gynecologic Oncology, Cancers, Frontiers in Immunology, Frontiers in Oncology, and the Journal of Clinical Oncology are acknowledged as the five most influential journals regarding immune checkpoint inhibitors for endometrial cancer. Makker Vicky emerged as the most influential author, while Memorial Sloan Kettering Cancer Center was identified as the most influential institution. Current research hotspots regarding immune checkpoint inhibitors in the treatment of endometrial cancer include microsatellite instability, mismatch repair deficiency, PD-1, PD-L1, chemotherapy, pembrolizumab, lenvatinib, and dostarlimab. Additionally, emerging trending topics in this field encompass pembrolizumab, lenvatinib, dostarlimab, immune checkpoint inhibitors, and mismatch repair deficiency.ConclusionAn in-depth exploration of the molecular mechanisms of immune checkpoint inhibitors for endometrial cancer is crucial for overcoming the current clinical challenges associated with immunotherapy. This study systematically analyzes the current state of research in this field, focusing on research hotspots, emerging trends, and future development directions. Additionally, it comprehensively evaluates the most influential literature, core journals, authoritative scholars, leading research institutions, and major contributing countries in this field.
